Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
NCT02836548Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2016
- Primary completion
- Nov 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in melanoma with BRAF V600 mutation, sponsored by Netherlands Cancer Institute. Primary endpoint: Anti-tumor response rate up to 24 months. Started Jun 2016; status: completed.
02
Drugs
vorinostat
03
Conditions
melanoma with BRAF V600 mutation
Beyond the preview
Go deeper on NCT02836548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836548.